Body dysmorphic disorder: Treatment and prognosis
- Katharine A Phillips, MD
Katharine A Phillips, MD
- Professor of Psychiatry and Human Behavior
- Warren Alpert Medical School of Brown University
Body dysmorphic disorder (BDD) is characterized by preoccupation with nonexistent or slight defects in physical appearance, such that patients believe that they look abnormal, unattractive, ugly, or deformed, when in reality they look normal. The preoccupation with perceived flaws leads to repetitive behaviors (eg, checking their appearance in mirrors), which are difficult to control and not pleasurable. BDD is common but usually under-recognized, causes distress and/or impaired functioning, and is often associated with suicidal ideation and behavior.
Patients with BDD may present to mental health professionals as well as other clinicians, such as dermatologists, plastic surgeons, primary care physicians, pediatricians, and dentists. Most patients seek nonpsychiatric treatment (most commonly dermatologic and surgical) for their perceived physical defects; this treatment appears to be ineffective for most patients and can be risky for clinicians to provide. By contrast, pharmacotherapy (ie, selective serotonin reuptake inhibitors or clomipramine) and/or cognitive-behavioral therapy tailored specifically to BDD are often efficacious.
This topic reviews the treatment and prognosis of BDD. The epidemiology, pathogenesis, clinical features, assessment, diagnosis, and differential diagnosis of BDD are discussed separately. (See "Body dysmorphic disorder: Epidemiology, pathogenesis, and clinical features" and "Body dysmorphic disorder: Assessment, diagnosis, and differential diagnosis".)
DIAGNOSIS OF BODY DYSMORPHIC DISORDER
●Preoccupation with at least one nonexistent or slight defect in physical appearance (eg, thinks about the perceived defects for at least one hour per day).
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington 2013.
- Phillips KA. Understanding Body Dysmorphic Disorder: An Essential Guide, Oxford University Press, New York 2009.
- Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image 2008; 5:13.
- Phillips KA. Pharmacotherapy for Body Dysmorphic Disorder. Psychiatr Ann 2010; 40:325.
- Bingel U, Placebo Competence Team. Avoiding nocebo effects to optimize treatment outcome. JAMA 2014; 312:693.
- Phillips KA, Kelly MM. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. Int Clin Psychopharmacol 2009; 24:26.
- Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:580.
- Sarwer DB, Crerand CE, Magee L. Body dysmorphic disorder in patients who seek appearance-enhancing medical treatments. Oral Maxillofac Surg Clin North Am 2010; 22:445.
- Crerand CE, Menard W, Phillips KA. Surgical and minimally invasive cosmetic procedures among persons with body dysmorphic disorder. Ann Plast Surg 2010; 65:11.
- Veale D, Anson M, Miles S, et al. Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: a randomised controlled trial. Psychother Psychosom 2014; 83:341.
- National Institute for Health and Clinical Excellence. Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. CG31. November, 2005. http://www.nice.org.uk/ (Accessed on September 04, 2014).
- Ipser JC, Sander C, Stein DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev 2009; :CD005332.
- Phillips KA. Body dysmorphic disorder. In: Handbook on Obsessive-Compulsive and Related Disorders, Phillips KA, Stein DJ. (Eds), American Psychiatric Publishing, Arlington, VA 2015.
- Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 2002; 59:381.
- Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 1999; 56:1033.
- Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol 2006; 21:177.
- Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998; 59:165.
- Phillips KA, Keshaviah A, Dougherty DD, et al. Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial. Am J Psychiatry 2016; 173:887.
- Phillips KA, Albertini RS, Siniscalchi JM, et al. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry 2001; 62:721.
- Wilhelm S, Phillips KA, Steketee G. Cognitive-Behavioral Therapy for Body Dysmorphic Disorder: A Treatment Manual, The Guilford Press, New York 2013.
- Veale D, Neziroglu F. Body Dysmorphic Disorder: A Treatment Manual, John Wiley & Sons, Chichester 2010.
- Buhlmann U, Reese HE, Renaud S, Wilhelm S. Clinical considerations for the treatment of body dysmorphic disorder with cognitive-behavioral therapy. Body Image 2008; 5:39.
- Veale D, Gournay K, Dryden W, et al. Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial. Behav Res Ther 1996; 34:717.
- Rosen JC, Reiter J, Orosan P. Cognitive-behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol 1995; 63:263.
- Wilhelm S, Phillips KA, Didie E, et al. Modular cognitive-behavioral therapy for body dysmorphic disorder: a randomized controlled trial. Behav Ther 2014; 45:314.
- Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull 1996; 32:175.
- Nakaaki S, Murata Y, Furukawa TA. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. Psychiatry Clin Neurosci 2008; 62:370.
- Uzun O, Ozdemir B. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Clin Drug Investig 2010; 30:707.
- Phillips KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 2005; 162:377.
- Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 2005; 162:1022.
- Allen A, Hadley SJ, Kaplan A, et al. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr 2008; 13:138.
- Phillips KA, Menard W. A prospective pilot study of levetiracetam for body dysmorphic disorder. CNS Spectr 2009; 14:252.
- Nardi AE, Lopes FL, Valença AM. Body dysmorphic disorder treated with bupropion: cases report. Aust N Z J Psychiatry 2005; 39:112.
- Canan F, Sinani G, Aydinoglu U. Body dysmorphic disorder incidentally treated with bupropion: a case report. J Clin Psychopharmacol 2013; 33:133.
- Brown GK, Henriques GR, Ratto C, Beck AT. Cognitive Therapy Treatment Manual for Suicide Attempters, University of Pennsylvania, Philadelphia 2002.
- DIAGNOSIS OF BODY DYSMORPHIC DISORDER
- GENERAL TREATMENT PRINCIPLES
- Approach to the patient
- Cosmetic interventions
- MILD TO MODERATE ILLNESS
- Approach to treatment
- Initial treatment
- - Pharmacotherapy
- - Cognitive-behavioral therapy
- Treatment resistant patients
- Treatment refractory patients
- Other options
- SEVERE ILLNESS
- First line
- Treatment resistance
- MAINTENANCE TREATMENT
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS